Cargando…

Examining the Effects of Dasatinib, Sorafenib, and Nilotinib on Vascular Smooth Muscle Cells: Insights into Proliferation, Migration, and Gene Expression Dynamics

Background: Dasatinib, nilotinib, and sorafenib are clinically proven tyrosine kinase inhibitors (TKIs) used for the treatment of leukemia and hepatocellular carcinoma. However, there is a growing concern regarding cardiotoxicity associated with their use. The impact of these TKIs on vascular smooth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alhazzani, Khalid, Almangour, Abdullah, Alsalem, Abdulaziz, Alqinyah, Mohammed, Alhamed, Abdullah S., Alhamami, Hussain N., Alanazi, Ahmed Z.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594443/ https://www.ncbi.nlm.nih.gov/pubmed/37873791 http://dx.doi.org/10.3390/diseases11040147

Ejemplares similares

The Potential Protective Role of Naringenin against Dasatinib-Induced Hepatotoxicity
por: Alanazi, Ahmed Z., et al.
Publicado: (2023)

Targeting Store-Operated Calcium Entry Regulates the Inflammation-Induced Proliferation and Migration of Breast Cancer Cells
por: Alqinyah, Mohammed, et al.
Publicado: (2023)

Blockade of store-operated calcium entry sensitizes breast cancer cells to cisplatin therapy via modulating inflammatory response
por: Alhamed, Abdullah S., et al.
Publicado: (2023)

Augmented antitumor effects of erlotinib and cabozantinib on A549 non-small cell lung cancer: In vitro and in vivo studies
por: Alhazzani, Khalid, et al.
Publicado: (2023)

Protective role of Dodonaea viscosa extract against streptozotocin-induced hepatotoxicity and nephrotoxicity in rats
por: Alanazi, Ahmed Z., et al.
Publicado: (2023)

Patient Adherence and Persistence with Imatinib, Nilotinib, Dasatinib in Clinical Practice
por: Santoleri, Fiorenzo, et al.
Publicado: (2013)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

Adherence to evidence-based guidelines for the management of pneumonia in a tertiary teaching hospital in Riyadh
por: Alessa, Mohammed, et al.
Publicado: (2023)

Dasatinib-induced Reversible Demyelinating Peripheral Neuropathy and Successful Conversion to Nilotinib in Chronic Myelogenous Leukemia
por: Inoue, Hiroyasu, et al.
Publicado: (2020)

Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia
por: Han, Jae Joon
Publicado: (2023)

Angiotensin II type 1 receptor blockade attenuates gefitinib-induced cardiac hypertrophy via adjusting angiotensin II-mediated oxidative stress and JNK/P38 MAPK pathway in a rat model
por: Alanazi, Wael A., et al.
Publicado: (2022)

Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients
por: Breccia, Massimo, et al.
Publicado: (2017)

A validated UPLC–MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma
por: Zeng, Jing, et al.
Publicado: (2017)

A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer
por: Archibald, Monica, et al.
Publicado: (2016)

Valsartan prevents gefitinib-induced lung inflammation, oxidative stress, and alteration of plasma metabolites in rats
por: Alanazi, Wael A., et al.
Publicado: (2023)

Knowledge regarding Zika Virus Infection among Healthcare Providers in an Academic Tertiary Care Center in Riyadh, Saudi Arabia: A Cross-Sectional Survey Study
por: Alessa, Mohammed, et al.
Publicado: (2020)

Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line
por: Okabe, Seiichi, et al.
Publicado: (2011)

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
por: Uz, B., et al.
Publicado: (2011)

Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
por: Cortes, Jorge E., et al.
Publicado: (2016)

Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high‐performance liquid chromatography–Photodiode array detection
por: Yokoyama, Yuta, et al.
Publicado: (2022)

OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2014)

Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib
por: Häselbarth, Lukas, et al.
Publicado: (2023)

Antidepressants and health-related quality of life (HRQoL) for patients with depression: Analysis of the medical expenditure panel survey from the United States
por: Almohammed, Omar A., et al.
Publicado: (2022)

The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis
por: Mealing, Stuart, et al.
Publicado: (2013)

Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy
por: Woywod, Clemens, et al.
Publicado: (2017)

Assessment of Dasatinib Versus Nilotinib as Upfront Therapy for Chronic Phase of Chronic Myeloid Leukemia in Qatar: A Cost-Effectiveness Analysis
por: Adel, Ahmad, et al.
Publicado: (2021)

Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib
por: Dessilly, Géraldine, et al.
Publicado: (2016)

Successful treatment with nilotinib after bosutinib-induced pulmonary arterial hypertension recurrence following dasatinib in chronic myeloid leukemia in chronic phase
por: Takatsuka, Ibuki, et al.
Publicado: (2022)

Examining the Early Period Effect of Nilotinib on Hearing: An Experimental Study
por: Bora, Adem, et al.
Publicado: (2020)

Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings
por: Cheng, Fang, et al.
Publicado: (2023)

An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: A CHEERS-compliant article
por: Wu, Bin, et al.
Publicado: (2017)

Elucidation of the Molecular Mechanisms Underlying Sorafenib-Induced Hepatotoxicity
por: AlAsmari, Abdullah F., et al.
Publicado: (2020)

Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors – a single center experience
por: Ribeiro, Beatriz Felicio, et al.
Publicado: (2015)

ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells
por: Eadie, Laura N., et al.
Publicado: (2018)

Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy
por: Bonifacio, Massimiliano, et al.
Publicado: (2021)

Emerging regulators of vascular smooth muscle cell migration
por: Afewerki, TecLino, et al.
Publicado: (2019)

Correction: ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells
Publicado: (2018)

The Optimization and Evaluation of Flibanserin Fast-Dissolving Oral Films
por: Alghaith, Adel F., et al.
Publicado: (2022)

Neuroinflammatory Cytokines Induce Amyloid Beta Neurotoxicity through Modulating Amyloid Precursor Protein Levels/Metabolism
por: Alasmari, Fawaz, et al.
Publicado: (2018)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d2rpatdvc5g5nvngrhvvqqou6g